Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Xilio Therapeutics, Inc. (XLO)

Xilio Therapeutics Q2 net loss narrows to $6.4 million on higher collaboration revenue

Positive Impact 3 of 5 earnings Written later

Xilio Therapeutics reported second quarter 2026 results, with collaboration and license revenue rising to $18.7 million from $8.1 million a year earlier and the net loss narrowing to $6.4 million from $15.8 million. The company also said the FDA cleared its IND application for XTX501, and it expects existing cash to fund operations into the first quarter of 2028.

Key points

  • Collaboration and license revenue was $18.7 million for the quarter ended June 30, 2026, compared with $8.1 million a year earlier, driven by agreements with AbbVie and Gilead.
  • Net loss was $6.4 million, compared with $15.8 million for the same quarter of 2025.
  • The FDA cleared the IND application for XTX501 to proceed to a Phase 1/2 trial; dosing in the Phase 1 portion is expected in the second half of 2026.
  • Cash and cash equivalents were $136.0 million as of June 30, 2026, with runway expected into the first quarter of 2028.

The filing

CompanyXilio Therapeutics, Inc. (XLO)
Form8-K, current report
Filed with the SECAug 12, 2026, 7:35 AM ET
Accession number0001193125-26-345753

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.